17 July 2024 - Shanghai Junshi Biosciences announced that the National Medical Products Administration has accepted for review the supplemental new ...
10 July 2024 - AHB-137 gains breakthrough therapy designation from the NMPA based on Phase 1/Phase2a clinical trial data demonstrating safety ...
5 July 2024 - Results from the registrational SEARCH study in China showed that the overall response rate among the ...
2 July 2024 - Gyre Therapeutics today announced that China’s National Medical Products Administration has approved Gyre Pharmaceuticals’ avatrombopag maleate tablets ...
4 July 2024 - - Hutchmed (China) today announces that the new drug application for tazemetostat for the treatment of ...
2 July 2024 - Approval marks Xtandi’s third indication for advanced prostate cancer in China. ...
27 June 2024 - China is the third country to launch Leqembi following the United States and Japan. ...
26 June 2024 - Approval based on FLAURA2 results which showed Tagrisso plus chemotherapy reduced the risk of disease progression ...
19 June 2024 - Golidocitinib is a first-in-class Janus kinase 1 only inhibitor approved for the treatment of relapsed/refractory PTCL based ...
31 May 2024 - Separate and distinct from HARMONi-2 announcement, HARMONi-A showed clinically meaningful and statistically significant benefit: progression-free survival hazard ...
12 May 2024 - The approval is based on the pivotal TRIDENT-1 trial, in which Augtyro achieved a high response ...
28 March 2024 - Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival vs platinum-containing ...
1 March 2024 - CARsgen Therapeutics announces that today the National Medical Products Administration of China has approved the new drug ...
10 January 2024 - Approval based on a separate Phase 3 trial among Chinese patients reinforcing mepolizumab’s efficacy and safety ...
9 January 2024 - BioArctic's partner Eisai announced today that Leqembi (lecanemab-irmb) has been approved in China as a treatment for ...